Background: The stability of ophthalmic preparations in multidose containers is influenced by the preservative as well as the stability of the active ingredient. Unstable drugs may require refrigeration to preserve their active ingredient level and they are more likely to degrade over time, therefore becoming more susceptible to degradation based on patient mishandling. The purpose of this study was to determine the degree of molecular degradation that occurs in bimatoprost and latanoprost in a patient-use setting.
Methods: This was an open-label, laboratory evaluation of the relative stability of bimatoprost and latanoprost. Patients presently using bimatoprost (n = 31) or latanoprost (n = 34) were identified at 2 clinical sites in Brazil. Patients were instructed to use and store their drops as usual and return all used medication bottles between day 28 and day 34 after opening.
Results: Bimatoprost demonstrated no degradation, but latanoprost degraded at various levels. The mean age of bimatoprost was 43.0 +/- 3.4 days and the mean age of latanoprost was 43.9 +/- 2.8 days (P = .072). The mean percentage of labeled concentration was 103.7% in the bimatoprost bottles and 88.1% in the latanoprost bottles (P < 001).
Conclusion: This study showed that bimatoprost maintained > or =100% concentration throughout the study period while latanoprost did not.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442051 | PMC |
| http://dx.doi.org/10.1186/1471-2415-8-11 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Changes in prostaglandin-associated periorbital syndrome: a self-controlled and prospective study.
Cutan Ocul Toxicol
December 2024
Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China.
Article Synopsis
- The study investigated the incidence of the prostaglandin-associated periorbital syndrome (PAPS) in patients with primary open-angle glaucoma or ocular hypertension after using topical prostaglandin analogues (PGAs) for 3-6 months.
- Among the 55 patients studied, key indicators such as interpupillary distance and exophthalmos were measured, alongside subjective assessments of periocular changes, showing significant changes primarily at the 1 and 3-month marks.
- Results indicated that bimatoprost resulted in the highest incidence of PAPS, with noticeable periorbital changes like eyelash growth and hyperpigmentation increasing over time.
A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study.
Contemp Clin Trials
December 2024
Author Employee of Nicox Ophthalmics, Nicox Ophthalmics, Inc. 4819 Emperor Blvd. Suite 400 Durham, NC 27703, United States.
Purpose: To identify the optimal dose of NCX 470, a nitric oxide (NO)-donating bimatoprost, for comparison to latanoprost in a phase 3 trial for open-angle glaucoma (OAG) or ocular hypertension (OHTN) using an adaptive dose selection design.
Patients And Methods: In this prospective, multicenter trial, subjects were randomized 1:1:1 to NCX 470 0.065 %, NCX 470 0.
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database.
Ther Adv Drug Saf
October 2024
Xiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen University, 401 Chengyi Build, Xiang-an Campus of Xiamen University, South Xiang-an Road, Xiamen, Fujian 361005, China.
Article Synopsis
- - The study investigates common adverse events related to four prostaglandin medications used for glaucoma (latanoprost, bimatoprost, travoprost, and tafluprost) using the FDA's Adverse Event Reporting System (FAERS) database.
- - It involves a detailed statistical analysis of adverse event data, revealing that eye disorders, particularly iris hyperpigmentation and corneal irritation, are significant issues associated with these drugs.
- - The findings indicate that adverse events occur differently over time across the medications, with latanoprost leading to longer onset times compared to bimatoprost, although the data can't definitively imply cause and effect.
Evaluation of the Effect of Topical Prostaglandin Analog Treatment on Orbital Structures in Open-Angle Glaucoma with Computed Tomography.
J Clin Med
September 2024
Department of Radiology, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.
: This study aims to evaluate the computed tomography (CT) scans of glaucoma patients using prostaglandin analogs (PGA) in one eye, investigate findings associated with prostaglandin-associated periorbitopathy (PAP), and compare these findings with those of the contralateral eyes. : Patients with open-angle glaucoma who had CT images of the orbital region taken for another reason at least one month after starting PGA treatment in one eye were included in the study. Enophthalmos measurements from thin-slice CT images, along with 3D volume measurements of orbital fat tissue, periorbital muscles, and the optic nerve, were performed.
View Article and Find Full Text PDFProstaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database.
BMJ Open Ophthalmol
August 2024
Pharmacovigilance Department, Laboratorios Sophia SA de CV, Zapopan, Jalisco, Mexico.
Objective: This study aims to identify safety signals of ophthalmic prostaglandin analogues through data mining the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Methods: A data mining search by proportional reporting ratio, reporting OR, Bayesian confidence propagation neural network, information component 0.25 and χ for safety signals detection was conducted to the FAERS database for the following ophthalmic medications: latanoprost, travoprost, tafluprost and bimatoprost.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!